SS-31 (Elamipretide) – The World’s Most Advanced Mitochondria-Targeted Cardioprotective Peptide.

Want to Buy SS-31 Peptide Online? for longevity researchers, cardiologists, and mitochondrial biologists seeking the most precisely targeted, clinically advanced, and mechanistically unique mitochondrial protective compound available, SS-31 (Elamipretide) represents the absolute pinnacle of mitochondria-targeted peptide science. As the world’s only peptide specifically engineered to penetrate the inner mitochondrial membrane and directly protect cardiolipin — the most critical phospholipid for electron transport chain function and ATP synthesis — SS-31 delivers cardiac protection, mitochondrial restoration, and cellular energy enhancement that defines an entirely new category of therapeutic research compounds. Find pharmaceutical-grade SS-31 for sale now at Collagenpeptideseu — your verified, trusted source for premium mitochondrial research peptides.

What Makes SS-31 Unique Among All Research Peptides?

SS-31, scientifically designated Elamipretide and also known by its research name MTP-131, belongs to the Szeto-Schiller (SS) family of mitochondria-targeted peptides — developed through a decade of collaboration between Dr. Hazel Szeto (Cornell University) and Peter Schiller. What distinguishes SS-31 from every other research peptide available today is its extraordinary targeting specificity:

While virtually all other research peptides operate at the cell surface receptor level — binding to membrane receptors and triggering intracellular signaling cascades — SS-31 physically penetrates through the cell membrane, through the outer mitochondrial membrane, and concentrates specifically at the inner mitochondrial membrane (IMM), where it binds directly to cardiolipin — the unique tetra-acyl phospholipid found almost exclusively at the IMM.

This cardiolipin-targeted mechanism is precisely why SS-31’s research outcomes — documented in hundreds of published studies across cardiac, muscular, neurological, and metabolic research models — cannot be replicated by any other compound in the research peptide space. No upstream signaling pathway activation, no receptor-mediated cascade, no indirect mitochondrial support — direct, physical cardiolipin binding and protection at the molecular epicenter of cellular energy production.

SS-31 vs MOTS-C – The Mitochondrial Research Peptide Comparison

The SS-31 vs MOTS-C comparison is the most frequently researched topic in mitochondrial peptide science — representing two fundamentally different but powerfully complementary approaches to mitochondrial optimization:

Mechanism Comparison

• SS-31 targets the structural integrity of the inner mitochondrial membrane through direct cardiolipin binding — a physical, structural protection mechanism
• MOTS-C operates as a retrograde mitochondrial signal traveling from mitochondria to the cell nucleus — activating AMPK and metabolic gene regulatory programs through nuclear transcription

Research Application Comparison

The Synergistic Case

SS-31 vs MOTS-C is not a competition — it is the most compelling argument for combination therapy in mitochondrial research. SS-31 preserves the structural and functional integrity of the mitochondrial membrane while MOTS-C optimizes the metabolic signaling programs that determine how efficiently those mitochondria operate. Together they represent the most comprehensive mitochondrial health protocol available — addressing both the hardware (membrane structure) and software (metabolic gene programs) of cellular energy production simultaneously.

SS-31 Cardioprotective Research – The Clinical Evidence

SS-31’s most extensively documented and clinically advanced research application is cardiac protection — where its cardiolipin-targeted mechanism has produced some of the most remarkable outcomes ever documented in cardiovascular peptide research:

Myocardial Ischemia-Reperfusion Injury: Published research across multiple animal models has demonstrated that SS-31 administration at the time of reperfusion produces dramatic reductions in myocardial infarct size — with some studies reporting infarct size reductions of 40–50% compared to controls. This cardioprotective effect occurs through:

• Reduced mitochondrial permeability transition pore (mPTP) opening
• Maintained cardiolipin integrity preventing cytochrome c release
• Preserved ETC supercomplex organization during reperfusion stress
• Reduced ROS burst during the critical reperfusion window

Heart Failure with Preserved Ejection Fraction (HFpEF): SS-31 (Elamipretide) is currently in Phase 2/3 clinical trials for HFpEF — one of the most treatment-resistant forms of heart failure — with published Phase 2 data demonstrating improvements in 6-minute walk distance, quality of life scores, and cardiac biomarkers following short-course SS-31 treatment.

Barth Syndrome: FDA Orphan Drug designation has been granted for SS-31 in Barth syndrome — a rare genetic disorder characterized by cardiolipin deficiency. Clinical research has demonstrated that SS-31 can partially compensate for genetic cardiolipin insufficiency — directly validating the cardiolipin-binding mechanism that defines SS-31’s entire pharmacological rationale.

Key SS-31 Peptide Benefits Across Research Domains

Buy SS-31 peptide research consistently documents outstanding outcomes:

Mitochondrial Function:

• Cardiolipin stabilization — prevents oxidative degradation of the IMM’s most critical structural lipid
• ETC supercomplex organization — restores the spatial organization of complexes I-IV for maximum electron transfer efficiency
• Reduced mitochondrial ROS — improved electron transfer efficiency dramatically reduces superoxide and hydrogen peroxide generation
• Restored membrane potential — maintained electrochemical gradient enables efficient ATP synthesis

Musculoskeletal:

• Improved exercise tolerance — documented in multiple aging and disease research models
• Muscle regeneration — enhanced satellite cell function and fiber repair in aged tissue
• Reduced exercise-induced mitochondrial damage — protection of muscle mitochondria during high-intensity effort

Neurological:

• Neuroprotection — documented in ischemic brain injury and neurodegenerative models
• Cognitive preservation — improved mitochondrial function in neural tissue supports cognitive performance
• Reduced neuroinflammation — downstream anti-inflammatory effects of ROS reduction

Anti-Aging & Longevity:

• Reversal of age-related mitochondrial decline — landmark published data demonstrating restoration of aged mitochondrial function toward young phenotype
• Reduced systemic oxidative stress — mitochondria-targeted ROS reduction benefits the entire organism
• Cellular senescence reduction — improved mitochondrial function delays senescence onset

SS-31 Peptide Dose – Complete Research Protocol Guide

The SS-31 peptide dose parameters most referenced across published research and clinical trial literature:

Published In Vivo Research Dosing

• Cardiac protection: 3–10mg/kg SubQ or IV at time of ischemia-reperfusion
• Chronic mitochondrial support: 3mg/kg/day SubQ for ongoing protocols
• Aging research: 3mg/kg/day for 8–12 week intervention periods

Practical Human Research Reference Dosing

• Conservative starting dose: 0.1–0.25mg SubQ once daily
• Standard research dose: 0.5–1mg SubQ once daily
• Advanced protocol: 1–2mg SubQ once daily (experienced researchers)
• Timing: Morning administration preferred for metabolic alignment
• Reconstitution: Dissolve in sterile saline; store at -20°C lyophilized; reconstituted stable at 4°C for 7 days; protect from light at all times
• Important: SS-31 is extremely potent at nanomolar concentrations — start conservatively and titrate based on individual response and research parameters

Why Buy SS-31 from Collagenpeptideseu

The synthesis of SS-31 requires precise construction of its alternating aromatic-cationic tetrapeptide sequence — including the critical D-Arg stereoisomer at position 1 and the dimethylated tyrosine residue at position 2. Both modifications are essential for cardiolipin binding activity — and both are frequently incorrect in lower-quality synthesis runs. When you buy SS-31 from Collagenpeptideseu, every vial is independently verified to confirm:

• ✔ Correct D-Arg stereochemistry at position 1
• ✔ Accurate dimethyl-Tyr modification at position 2
• ✔ Full tetrapeptide sequence integrity — Arg-Dmt-Lys-Phe-NH2 confirmed
• ✔ Third-party HPLC and mass spectrometry — independent purity and molecular weight verification
• ✔ Endotoxin testing — sterile, pyrogen-free for injectable research use
• ✔ Competitive global pricing — best value for Phase 2/3-equivalent mitochondrial research peptide
• ✔ Discreet, cold-chain packaging — maintaining peptide integrity throughout transit
• ✔ Real-time shipment tracking — full order visibility from purchase to delivery
• ✔ Expert multilingual support — English, German, French, Spanish, and Portuguese

Order SS-31 Today

Whether you’re researching cardiac ischemia-reperfusion protection, heart failure pharmacology, mitochondrial aging biology, muscle regeneration, neuroprotection, or the most comprehensive mitochondrial health protocol with MOTS-C, SS-31 (Elamipretide) delivers the most mechanistically precise and clinically advanced mitochondria-targeted peptide available in 2025.

Buy SS-31 peptide from the most trusted source — order now at Collagenpeptideseu and access the full cardioprotective and mitochondrial regenerative potential of SS-31 science.

This product is intended for research purposes only. Always consult a licensed healthcare professional before beginning any SS-31 or mitochondrial peptide research protocol.